Back to journals
Academic JournalOpen Access

Translational Psychiatry

30 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants

This double-blind, randomised, placebo-controlled crossover study and separate open-label dose-escalation study (n=36) in healthy participants examined intravenous DMT and found that it produced very strong but short-lived subjective effects, peaking within 2 minutes and fading within 12 to 30 minutes. The strongest effects levelled off at 15 mg, and dose escalation appeared to improve tolerability compared with blinded dosing.

Published
Journal
Translational Psychiatry
Authors
Erne, L., Mueller, L., Straumann, I., Ademaj, B., Eckert, A., Vukalovic, I., Valenta, J., Luethi, D., Liechti, M. E., Vogt, S. B.
Open Accessindividual

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial

In a double-blind randomised trial of patients with long-standing moderate-to-severe depression, two doses of psilocybin plus placebo and six weeks of escitalopram produced comparable reductions in negative affective bias on a facial emotion recognition task at the six-week endpoint. Changes in bias were not associated with concurrent symptom change, although improved recognition of positive faces predicted symptom improvement at week 10 only in the escitalopram group, suggesting partially overlapping but distinct cognitive mechanisms.

Published
Journal
Translational Psychiatry
Authors
Martens, M. A. G., Cunha, B. G., Erritzoe, D., Nutt, D., Carhart-Harris, R., Harmer, C. J.
Open Accessmeta

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis

This cost-effectiveness analysis found that psilocybin-assisted therapy (PAT) for treatment-resistant depression (TRD) may offer economic value at $5,000 or less per treatment course, yielding an incremental cost-effectiveness ratio of $117,517 per QALY gained over 12 months, with cost-effectiveness highly sensitive to treatment price (95% probability at $3,000 vs 1% at $10,000).

Published
Journal
Translational Psychiatry
Authors
Avancena, A. L. V., Vuong, L., Kahn, J. G., Marseille, E.
Open Accessmeta

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology

This systematic review (2024) and meta-analysis (s=44) finds that medium/high doses of LSD yield higher ratings of visionary restructuralisation than psilocybin. It also reports that psychedelics strengthen between-network functional connectivity and diminish within-network connectivity, and that LSD induces more inositol phosphate formation at the 5-HT2A receptor than DMT or psilocin, while receptor selectivity differences remain negligible.

Published
Journal
Translational Psychiatry
Authors
Shinozuka, K., Jerotic, K., Mediano, P. A. M., Zhao, A. T., Preller, K. H., Carhart-Harris, R. L., Kringelbach, M. L.
Open Accessindividual

Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects

In a randomized double‑blind placebo‑controlled crossover study in 16 healthy volunteers, oral mescaline (100–800 mg) produced dose‑dependent subjective and autonomic effects with dose‑proportional pharmacokinetics (Tmax ≈2 h, t1/2 ≈3.5 h) and increasing duration (6.4–14 h), with reduced tolerability and frequent nausea/emesis at 800 mg. Co‑administration of the 5‑HT2A antagonist ketanserin markedly attenuated and shortened the effects of 800 mg mescaline, indicating that its acute effects are primarily mediated by 5‑HT2A receptors.

Published
Journal
Translational Psychiatry
Authors
Klaiber, A., Schmid, Y., Becker, A. M., Straumann, I., Erne, L., Jelusic, A., Thomann, J., Luethi, D., Liechti, M. E.
Open Accessindividual

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience

This open-label study (n=8) co-administered psilocybin (25mg) with the amnestic benzodiazepine midazolam to assess the role of memory in the therapeutic effects of psilocybin. It finds that midazolam partially impaired memory while allowing a conscious psychedelic experience, with memory impairment inversely associated with salience, insight, and well-being induced by psilocybin, suggesting a role for memory in its therapeutic effects.

Published
Journal
Translational Psychiatry
Authors
Nicholas, C. R., Banks, M. I., Lennertz, R. L., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R. F., Hutson, P. R., Sauder, C. J., Dunne, J. D., Roseman, L., Raison, C. L., Banks, M. I.

Quick Facts

Papers Indexed
30
h-Index
137
Open Access
Yes
Publisher
Nature Portfolio
Country
United Kingdom
Website
Visit